awmsg logo



eltrombopag (Revolade®)


Reference No. 2595

Publication date:
11/01/2016


Appraisal information

eltrombopag (Revolade®) 25 mg film-coated tablet
eltrombopag (Revolade®) 50 mg film-coated tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 06/01/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, eltrombopag (Revolade®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with acquired severe aplastic anaemia who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haemoatopoietic stem cell transplantation.
Statement of Advice (SOA)
Download